Moderna’s CEO Stéphane Bancel discusses the transformative potential of mRNA technology in developing a personalized cancer vaccine, intismeran, and its implications for the future of medicine.
CAMBRIDGE, Massachusetts — On October 19, 2026, Stéphane Bancel, the Chief Executive Officer of Moderna, shared his vision for the future of medicine from his office at the company’s headquarters. This moment comes just weeks before the anticipated public release of promising data on the company’s first messenger RNA (mRNA) cancer vaccine, intismeran. Bancel reflected on the challenges and successes that have marked Moderna’s journey from a startup with untested technology to a leader in the field of biotechnology.
Fifteen years ago, Bancel himself had reservations about the viability of mRNA as a therapeutic platform. At that time, no mRNA-based products were approved, and prevailing scientific consensus suggested that mRNA was too unstable for medical applications. Instead, the biotech industry had largely focused on DNA manipulation, which offered more reliability. Bancel recounted his initial skepticism: “It was crazy to think of using mRNA as a drug.” However, a pivotal meeting changed his perspective, leading him to recognize that, with appropriate manipulation, mRNA could facilitate the development of entirely new classes of medicines.
Transforming Medicine with mRNA
Moderna’s objective has expanded beyond traditional drug development methods, aiming instead to create a versatile platform capable of producing various treatments in a modular fashion. Bancel likened this approach to how the tech industry builds software on foundational hardware and operating systems. He stated, “mRNA is the information molecule, so if you find a way to safely and effectively get it into the right cells, you can unlock a lot of medicines to help people’s suffering.” This vision has manifested in Moderna’s mRNA COVID vaccine, which is credited with saving an estimated two million lives globally and generating $46 billion in revenue from 2021 to 2024.
This fall, Moderna received approval for its mRNA flu vaccine, marking a significant milestone as the first of its kind. Moreover, an October announcement revealed that intismeran, in combination with one of Merck’s drugs, successfully demonstrated the ability to prevent the recurrence of melanoma in patients with mid- to late-stage disease. Bancel anticipates sharing similar encouraging results from another mRNA therapy aimed at a rare disease by year-end.
The Rapid Evolution of mRNA Applications
Over the past decade, mRNA has transitioned from a scientific curiosity to a pivotal player in biomedical innovation. Bancel’s determination to validate the skeptics has been instrumental in this transformation. He remarked, “At the beginning, it was either zero drugs, or we find a way to climb this mRNA mountain and make a lot of drugs.” Moderna’s mRNA technology allows for rapid vaccine development—scientists can create a vaccine against any pathogen in just six to eight weeks, significantly faster than traditional methods.
This rapidity is particularly beneficial in the field of cancer research, where personalized mRNA vaccines like intismeran are being developed. Bancel saw mRNA as an untapped resource for creating tailored therapies. Once correctly instructed, mRNA can enable the human body to act as its own treatment factory, producing the necessary proteins to combat diseases.
Bancel’s Journey and Vision
Bancel’s journey began in Marseilles, France, where an early interest in math and science was nurtured by his engineer father. He pursued a degree in chemical engineering before developing a passion for genetics. After earning an M.B.A. from Harvard Business School, Bancel held various roles in the pharmaceutical industry before becoming CEO of Moderna in 2011.
Under his leadership, Moderna has navigated the complexities of developing a startup based on unproven technology. Initially operating in stealth mode, the company faced skepticism and comparisons to fraudulent startups like Theranos. Bancel dismissed such comparisons, emphasizing the importance of giving the company time to develop its technology.
Despite the challenges, the company made significant strides, particularly in mRNA vaccine research. This progress was accelerated by the COVID-19 pandemic, which prompted a pivot of resources toward developing a vaccine against the virus. Bancel’s confidence in mRNA technology was bolstered by previous clinical trials that had shown promising results.
Intismeran and Future Prospects
As Moderna prepared to enroll patients for the intismeran study, the company faced the unprecedented challenge posed by COVID-19. Bancel decided to allocate most of Moderna’s resources to the pandemic response, a choice that was met with mixed reactions within the organization. Ultimately, the decision proved fruitful, as the development of the COVID vaccine validated the safety and efficacy of mRNA technology.
In October 2026, Moderna and Merck reported a significant 42% reduction in cancer recurrence among patients treated with intismeran and pembrolizumab, a combination therapy. This breakthrough has not only reinforced the potential of mRNA in oncology but has also opened avenues for further research. Bancel anticipates filing for FDA approval of intismeran soon and is actively exploring its applications in other cancer types.
Looking ahead, Bancel is realistic about the challenges faced by the biotech industry. He acknowledges the roller coaster nature of biopharmaceutical ventures but remains optimistic about the future of mRNA technology. He remarked, “I always think about the long cycle. I knew that if you can figure out the engineering puzzle of building a business with mRNA, then the impact of this technology on humanity… is going to be gigantic. And we are just beginning. We are just getting started.”
No Comment! Be the first one.